Vu L. Truong - 05 Dec 2022 Form 4 Insider Report for Aridis Pharmaceuticals, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Vu Truong
Issuer symbol
N/A
Transactions as of
05 Dec 2022
Net transactions value
$0
Form type
4
Filing time
07 Dec 2022, 08:02:59 UTC
Previous filing
08 Jun 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARDS Restricted Stock Units Award $0 +30,000 $0.000000 30,000 05 Dec 2022 Common Stock 30,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 15,000 shares of Common Stock will vest on June 5, 2023 and 15,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.